In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, 4D Molecular Therapeutics Inc’s stock clocked out at $6.53, down -3.12% from its previous closing price of $6.74. In other words, the price has decreased by -$3.12 from its previous closing price. On the day, 0.91 million shares were traded. FDMT stock price reached its highest trading level at $6.83 during the session, while it also had its lowest trading level at $6.43.
Ratios:
To gain a deeper understanding of FDMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.75 and its Current Ratio is at 8.75. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on January 13, 2025, Downgraded its rating to Market Perform and sets its target price to $15 from $40 previously.
On November 21, 2024, Morgan Stanley started tracking the stock assigning a Underweight rating and target price of $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 16 ’24 when Bizily Scott sold 500 shares for $16.33 per share. The transaction valued at 8,165 led to the insider holds 6,781 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FDMT now has a Market Capitalization of 304967328 and an Enterprise Value of 34819108. For the stock, the TTM Price-to-Sale (P/S) ratio is 10165.42 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at 1055.125 whereas that against EBITDA is -0.161.
Stock Price History:
The Beta on a monthly basis for FDMT is 2.84, which has changed by -0.5732026 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, FDMT has reached a high of $17.41, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is 29.82%, while the 200-Day Moving Average is calculated to be 32.64%.
Shares Statistics:
It appears that FDMT traded 1.10M shares on average per day over the past three months and 895940 shares per day over the past ten days. A total of 46.70M shares are outstanding, with a floating share count of 42.62M. Insiders hold about 8.75% of the company’s shares, while institutions hold 81.97% stake in the company. Shares short for FDMT as of 1755216000 were 4142441 with a Short Ratio of 3.36, compared to 1752537600 on 3619133. Therefore, it implies a Short% of Shares Outstanding of 4142441 and a Short% of Float of 9.229999999999999.
Earnings Estimates
Investors are keenly observing as 10.0 analysts analyze and rate the current performance of 4D Molecular Therapeutics Inc (FDMT) in the stock market.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.46 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$3.19 and -$3.98 for the fiscal current year, implying an average EPS of -$3.69. EPS for the following year is -$3.81, with 9.0 analysts recommending between -$2.8 and -$4.76.
